MedTrace Logo

Clinical Effectiveness of Advanced Hybrid Closed-loop Systems for Achieving Time in Tight Range Among T1D Patients

NCT06834334 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 189

Last updated 2026-03-19

No results posted yet for this study

Summary

Diabetes is a chronic disease with a relevant public health burden. Maintaining blood glucose levels as close to normal as possible is essential to avoid the associated microvascular and macrovascular complications. Therefore, the key to prevent and/or reduce the development of these chronic complications lies in an adequate and strict glycemic control.

This study consist of a cross-sectional observational study among adult patients with type 1 diabetes (T1D). The main objective is to analyze the effect on time in tight range (TiTR, 70-140 mg/dL) of interstitial glucose between three different advanced hybrid closed-loop (AHCL) systems.

Conditions

  • Type 1 Diabetes (T1D)

Interventions

DEVICE

MM780G

SmartGuard in Medtronic Minimed 780G advaced hybrid closed-loop

DEVICE

TTSX2

Control-IQ in Tandem T Slim X2 advanced hybrid closed-loop

DEVICE

CamAPS

CamAPS Fx in Ypsopump advanced hybrid closed-loop

Sponsors & Collaborators

  • Servicio Extremeño de Salud (Spain)

    collaborator UNKNOWN

  • Hospital Universitari Mutua Terrassa

    collaborator UNKNOWN

  • Castilla-La Mancha Health Service

    lead OTHER

Principal Investigators

  • Jesus Moreno Fernandez, PhD · Castilla-La Mancha Health Public Service

Eligibility

Min Age
18 Years
Max Age
99 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-02-27
Primary Completion
2025-10-01
Completion
2025-10-01
FDA Device
Yes

Countries

  • Spain

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06834334 on ClinicalTrials.gov